{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:58:42Z","timestamp":1785268722840,"version":"3.55.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Artificial intelligence (AI) is increasingly applied to clinical trial risk assessment, aiming to improve safety and efficiency. This scoping review analyzed 142 studies published between 2013 and 2024, focusing on safety (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200955), efficacy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200946), and operational (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200945) risk prediction. AI techniques, including traditional machine learning, deep learning (e.g., graph neural networks, transformers), and causal machine learning, are used for tasks like adverse drug event prediction, treatment effect estimation, and phase transition prediction. These methods utilize diverse data sources, from molecular structures and clinical trial protocols to patient data and scientific publications. Recently, large language models (LLMs) have seen a surge in applications, featuring in 7 out of 33 studies in 2023. While some models achieve high performance (AUROC up to 96%), challenges remain, including selection bias, limited prospective studies, and data quality issues. Despite these limitations, AI-based risk assessment holds substantial promise for transforming clinical trials, particularly through improved risk-based monitoring frameworks.\n                  <\/jats:p>","DOI":"10.1038\/s41746-025-01886-7","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:45:18Z","timestamp":1753836318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A scoping review of artificial intelligence applications in clinical trial risk assessment"],"prefix":"10.1038","volume":"8","author":[{"given":"Douglas","family":"Teodoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nona","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Bornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2014.4524","volume":"72","author":"ER Dorsey","year":"2015","unstructured":"Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A. & Kieburtz, K. Novel methods and technologies for 21st-Century clinical trials: a review. JAMA Neurol. 72, 582\u2013588 (2015).","journal-title":"JAMA Neurol."},{"key":"1886_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","volume":"311","author":"NS Downing","year":"2014","unstructured":"Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M. & Ross, J. S. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 311, 368\u2013377 (2014).","journal-title":"JAMA"},{"key":"1886_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J. & Baumann, M. How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics 39, 1243\u20131269 (2021).","journal-title":"PharmacoEconomics"},{"key":"1886_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2009.295","volume":"87","author":"JA DiMasi","year":"2010","unstructured":"DiMasi, J. A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272\u2013277 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.115.019902","volume":"133","author":"RJ Mentz","year":"2016","unstructured":"Mentz, R. J. et al. Good clinical practice guidance and pragmatic clinical trials. Circulation 133, 872\u2013880 (2016).","journal-title":"Circulation"},{"key":"1886_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s43441-021-00295-8","volume":"55","author":"B Barnes","year":"2021","unstructured":"Barnes, B. et al. Risk-based monitoring in clinical trials: past, present, and future. Ther. Innov. Regul. Sci. 55, 899 (2021).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"1886_CR7","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.clinthera.2018.04.020","volume":"40","author":"DK Agrafiotis","year":"2018","unstructured":"Agrafiotis, D. K. et al. Risk-based monitoring of clinical trials: an integrative approach. Clin. Ther. 40, 1204\u20131212 (2018).","journal-title":"Clin. Ther."},{"key":"1886_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/cpt.1347","volume":"105","author":"HP Selker","year":"2019","unstructured":"Selker, H. P. et al. Efficacy and effectiveness too trials: clinical trial designs to generate evidence on efficacy and on effectiveness in wide practice. Clin. Pharmacol. Ther. 105, 857\u2013866 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/10601333.2015.1046990","volume":"32","author":"M Simovi\u0107","year":"2015","unstructured":"Simovi\u0107, M. & Nikoli\u0107, N. Challenges of risk-based monitoring of clinical trials. Clin. Res. Regul. Aff. 32, 83\u201387 (2015).","journal-title":"Clin. Res. Regul. Aff."},{"key":"1886_CR10","doi-asserted-by":"publisher","first-page":"100643","DOI":"10.1016\/j.curtheres.2021.100643","volume":"95","author":"F Fneish","year":"2021","unstructured":"Fneish, F., Schaarschmidt, F. & Fortwengel, G. Improving risk assessment in clinical trials: toward a systematic risk-based monitoring approach. Curr. Ther. Res. 95, 100643 (2021).","journal-title":"Curr. Ther. Res."},{"key":"1886_CR11","doi-asserted-by":"publisher","first-page":"160940692110478","DOI":"10.1177\/16094069211047823","volume":"20","author":"PA Newman","year":"2021","unstructured":"Newman, P. A., Guta, A. & Black, T. Ethical considerations for qualitative research methods during the COVID-19 pandemic and other emergency situations: navigating the virtual field. Int. J. Qual. Methods 20, 16094069211047823 (2021).","journal-title":"Int. J. Qual. Methods"},{"key":"1886_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/pharmaceutics5010094","volume":"5","author":"B Yao","year":"2013","unstructured":"Yao, B., Zhu, L., Jiang, Q. & Xia, H. A. Safety monitoring in clinical trials. Pharmaceutics 5, 94\u2013106 (2013).","journal-title":"Pharmaceutics"},{"key":"1886_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","volume":"40","author":"S Harrer","year":"2019","unstructured":"Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence for clinical trial design. Trends Pharmacol. Sci. 40, 577\u2013591 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1886_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100413","volume":"3","author":"BA Badwan","year":"2023","unstructured":"Badwan, B. A. et al. Machine learning approaches to predict drug efficacy and toxicity in oncology. Cell Rep. Methods 3, 100413 (2023).","journal-title":"Cell Rep. Methods"},{"key":"1886_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.drudis.2019.12.014","volume":"25","author":"F Feijoo","year":"2020","unstructured":"Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S. & Albright, T. E. Key indicators of phase transition for clinical trials through machine learning. Drug Discov. Today 25, 414\u2013421 (2020).","journal-title":"Drug Discov. Today"},{"key":"1886_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-023-04698-z","volume":"23","author":"SA Alowais","year":"2023","unstructured":"Alowais, S. A. et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med. Educ. 23, 689 (2023).","journal-title":"BMC Med. Educ."},{"key":"1886_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.drudis.2021.09.006","volume":"27","author":"P Moingeon","year":"2022","unstructured":"Moingeon, P., Kuenemann, M. & Guedj, M. Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. Drug Discov. Today 27, 215\u2013222 (2022).","journal-title":"Drug Discov. Today"},{"key":"1886_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11192-020-03774-1","volume":"126","author":"EN Ngayua","year":"2021","unstructured":"Ngayua, E. N., He, J. & Agyei-Boahene, K. Applying advanced technologies to improve clinical trials: a systematic mapping study. Scientometrics 126, 1217\u20131238 (2021).","journal-title":"Scientometrics"},{"key":"1886_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12553-023-00738-2","volume":"13","author":"S Askin","year":"2023","unstructured":"Askin, S., Burkhalter, D., Calado, G. & El Dakrouni, S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol. 13, 203\u2013213 (2023).","journal-title":"Health Technol."},{"key":"1886_CR20","doi-asserted-by":"crossref","unstructured":"Weissler, E. H. et al. The role of machine learning in clinical research: transforming the future of evidence generation. Trials 22, 537 (2021).","DOI":"10.1186\/s13063-021-05489-x"},{"key":"1886_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/19466315.2020.1797867","volume":"12","author":"WR Zame","year":"2020","unstructured":"Zame, W. R. et al. Machine learning for clinical trials in the era of COVID-19. Stat. Biopharm. Res. 12, 506\u2013517 (2020).","journal-title":"Stat. Biopharm. Res."},{"key":"1886_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.12793\/tcp.2023.31.e16","volume":"31","author":"J-L Ghim","year":"2023","unstructured":"Ghim, J.-L. & Ahn, S. Transforming clinical trials: the emerging roles of large language models. Transl. Clin. Pharmacol. 31, 131\u2013138 (2023).","journal-title":"Transl. Clin. Pharmacol."},{"key":"1886_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","volume":"26","author":"D Paul","year":"2020","unstructured":"Paul, D. et al. Artificial intelligence in drug discovery and development. Drug Discov. Today 26, 80\u201393 (2020).","journal-title":"Drug Discov. Today"},{"key":"1886_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.imed.2021.10.001","volume":"2","author":"V Patel","year":"2022","unstructured":"Patel, V. & Shah, M. Artificial intelligence and machine learning in drug discovery and development. Intell. Med. 2, 134\u2013140 (2022).","journal-title":"Intell. Med."},{"key":"1886_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.tips.2019.07.005","volume":"40","author":"A Basile","year":"2019","unstructured":"Basile, A., Yahi, A. & Tatonetti, N. Artificial intelligence for drug toxicity and safety. Trends Pharmacol. Sci. 40, 624\u2013635 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1886_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-207","volume":"14","author":"E Bresso","year":"2013","unstructured":"Bresso, E. et al. Integrative relational machine-learning for understanding drug side-effect profiles. BMC Bioinformatics14, 207 (2013).","journal-title":"BMC Bioinformatics"},{"key":"1886_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40264-019-00831-4","volume":"42","author":"T M\u00e9nard","year":"2019","unstructured":"M\u00e9nard, T., Barmaz, Y., Koneswarakantha, B., Bowling, R. & Popko, L. Enabling data-driven clinical quality assurance: predicting adverse event reporting in clinical trials using machine learning. Drug Saf. 42, 1045\u20131053 (2019).","journal-title":"Drug Saf."},{"key":"1886_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18305-y","volume":"11","author":"D Galeano","year":"2020","unstructured":"Galeano, D., Li, S., Gerstein, M. & Paccanaro, A. Predicting the frequencies of drug side effects. Nat. Commun. 11, 4575 (2020).","journal-title":"Nat. Commun."},{"key":"1886_CR29","doi-asserted-by":"publisher","first-page":"1357630","DOI":"10.1155\/2020\/1357630","volume":"2020","author":"S Seo","year":"2020","unstructured":"Seo, S., Lee, T., Kim, M.-H. & Yoon, Y. Prediction of side effects using comprehensive similarity measures. BioMed. Res. Int. 2020, 1357630 (2020).","journal-title":"BioMed. Res. Int."},{"key":"1886_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04298-y","volume":"22","author":"R Masumshah","year":"2021","unstructured":"Masumshah, R., Aghdam, R. & Eslahchi, C. A neural network-based method for polypharmacy side effects prediction. BMC Bioinformatics22, 385 (2021).","journal-title":"BMC Bioinformatics"},{"key":"1886_CR31","doi-asserted-by":"publisher","first-page":"bbab239","DOI":"10.1093\/bib\/bbab239","volume":"22","author":"H Zhao","year":"2021","unstructured":"Zhao, H., Zheng, K., Li, Y. & Wang, J. A novel graph attention model for predicting frequencies of drug-side effects from multi-view data. Brief. Bioinformatics22, bbab239 (2021).","journal-title":"Brief. Bioinformatics"},{"key":"1886_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1109\/TCBB.2022.3141103","volume":"20","author":"OC Uner","year":"2023","unstructured":"Uner, O. C., Kuru, H. I., Cinbis, R. G., Tastan, O. & Cicek, A. E. DeepSide: A deep learning approach for drug side effect prediction. IEEE\/ACM Trans. Comput. Biol. Bioinformatics20, 330\u2013339 (2023).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinformatics"},{"key":"1886_CR33","doi-asserted-by":"crossref","unstructured":"Pancino, N., Perron, Y., Bongini, P. & Scarselli, F. Drug side effect prediction with deep learning molecular embedding in a Graph-of-Graphs domain. Mathematics 10, (2022).","DOI":"10.3390\/math10234550"},{"key":"1886_CR34","doi-asserted-by":"publisher","first-page":"100358","DOI":"10.1016\/j.crmeth.2022.100358","volume":"2","author":"D Galeano","year":"2022","unstructured":"Galeano, D. & Paccanaro, A. Machine learning prediction of side effects for drugs in clinical trials. Cell Rep. Methods 2, 100358 (2022).","journal-title":"Cell Rep. Methods"},{"key":"1886_CR35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1109\/TCBB.2022.3175362","volume":"20","author":"P Bongini","year":"2023","unstructured":"Bongini, P. et al. Modular multi-source prediction of drug side-effects with DruGNN. IEEE\/ACM Trans. Comput. Biol. Bioinformatics.20, 1211\u20131220 (2023).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinformatics."},{"key":"1886_CR36","unstructured":"Besharatifard, M., Ghorbanali, Z. & Zare Mirakabad, F. Adverse drug reaction prediction using voting ensemble training approach. AUT J. Math. Comput. 5, 45\u201359 (2024)."},{"key":"1886_CR37","unstructured":"L\u00f6nnroth, O. et al. Adverse event prediction using a task-specific generative model. In 3rd Workshop on Interpretable Machine Learning in Healthcare (IMLH) (Honolulu, Hawaii, USA, 2023)."},{"key":"1886_CR38","doi-asserted-by":"publisher","first-page":"107452","DOI":"10.1016\/j.compbiomed.2023.107452","volume":"165","author":"J Wu","year":"2023","unstructured":"Wu, J., Su, Y., Yang, A., Ren, J. & Xiang, Y. An improved multi-modal representation-learning model based on fusion networks for property prediction in drug discovery. Comput. Biol. Med. 165, 107452 (2023).","journal-title":"Comput. Biol. Med."},{"key":"1886_CR39","doi-asserted-by":"publisher","first-page":"1113007","DOI":"10.3389\/fphar.2023.1113007","volume":"14","author":"W Mangione","year":"2023","unstructured":"Mangione, W., Falls, Z. & Samudrala, R. Effective holistic characterization of small molecule effects using heterogeneous biological networks. Front. Pharmacol. 14, 1113007 (2023).","journal-title":"Front. Pharmacol."},{"key":"1886_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.4049\/jimmunol.2300185","volume":"212","author":"RH Pullen","year":"2024","unstructured":"Pullen, R. H. et al. A Predictive Model of Vaccine Reactogenicity Using Data from an In Vitro Human Innate Immunity Assay System. J. Immunol. 212, 904\u2013916 (2024).","journal-title":"J. Immunol."},{"key":"1886_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.techfore.2024.123232","volume":"201","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Identifying pharmaceutical technology opportunities from the perspective of adverse drug reactions: Machine learning in multilayer networks. Technol. Forecast. Soc. Change 201, 123232 (2024).","journal-title":"Technol. Forecast. Soc. Change"},{"key":"1886_CR42","doi-asserted-by":"publisher","first-page":"vbae009","DOI":"10.1093\/bioadv\/vbae009","volume":"4","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y., Seoighe, C. & Yang, H. Non-Negative matrix factorization combined with kernel regression for the prediction of adverse drug reaction profiles. Bioinform. Adv. 4, vbae009 (2024).","journal-title":"Bioinform. Adv."},{"key":"1886_CR43","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. TWIN-GPT: Digital Twins for Clinical Trials via Large Language Model. ACM Trans. Multimed. Comput. Commun. Appl. https:\/\/doi.org\/10.48550\/arXiv.2404.01273 (2024)","DOI":"10.48550\/arXiv.2404.01273"},{"key":"1886_CR44","doi-asserted-by":"publisher","unstructured":"Tong, L., Luo, J., Cisler, R. & Cantor, M. Machine learning-based modeling of big clinical trials data for adverse outcome prediction: A case study of death events. in 43rd Annual Computer Software and Applications Conference (COMPSAC) (IEEE, 2019). https:\/\/doi.org\/10.1109\/COMPSAC.2019.10218.","DOI":"10.1109\/COMPSAC.2019.10218"},{"key":"1886_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10729-021-09584-y","volume":"25","author":"A Kundu","year":"2022","unstructured":"Kundu, A., Feijoo, F., Martinez, D. A., Hermosilla, M. & Matis, T. Prospective adverse event risk evaluation in clinical trials. Health Care Manag. Sci. 25, 89\u201399 (2022).","journal-title":"Health Care Manag. Sci."},{"key":"1886_CR46","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/jat.4475","volume":"43","author":"G Karaduman","year":"2023","unstructured":"Karaduman, G. & Kelleci \u00c7elik, F. 2D-Quantitative structure\u2013activity relationship modeling for risk assessment of pharmacotherapy applied during pregnancy. J. Appl. Toxicol. 43, 1436\u20131446 (2023).","journal-title":"J. Appl. Toxicol."},{"key":"1886_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41746-023-00963-z","volume":"6","author":"EK Oikonomou","year":"2023","unstructured":"Oikonomou, E. K. et al. An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials. NPJ Digit. Med. 6, 217 (2023).","journal-title":"NPJ Digit. Med."},{"key":"1886_CR48","doi-asserted-by":"publisher","first-page":"1270443","DOI":"10.3389\/fphar.2023.1270443","volume":"14","author":"D Augustin","year":"2023","unstructured":"Augustin, D., Lambert, B., Robinson, M., Wang, K. & Gavaghan, D. Simulating clinical trials for model-informed precision dosing: using warfarin treatment as a use case. Front Pharm. 14, 1270443 (2023).","journal-title":"Front Pharm."},{"key":"1886_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56561-w","volume":"14","author":"Y Levi","year":"2024","unstructured":"Levi, Y., Brandeau, M. L., Shmueli, E. & Yamin, D. Prediction and detection of side effects severity following COVID-19 and influenza vaccinations: utilizing smartwatches and smartphones. Sci. Rep. 14, 6012 (2024).","journal-title":"Sci. Rep."},{"key":"1886_CR50","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1073\/pnas.1516645112","volume":"112","author":"MP Schwartz","year":"2015","unstructured":"Schwartz, M. P. et al. Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. Proc. Natl Acad. Sci. Usa. 112, 12516\u201312521 (2015).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1886_CR51","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.chembiol.2016.07.023","volume":"23","author":"K Gayvert","year":"2016","unstructured":"Gayvert, K., Madhukar, N. & Elemento, O. A data-driven approach to predicting successes and failures of clinical trials. Cell Chem. Biol. 23, 1294\u20131301 (2016).","journal-title":"Cell Chem. Biol."},{"key":"1886_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00018","volume":"1","author":"F Seyednasrollah","year":"2017","unstructured":"Seyednasrollah, F. et al. A DREAM challenge to build prediction models for short-term discontinuation of Docetaxel in metastatic castration-resistant prostate cancer. JCO Clin. Cancer Inform. 1, 1\u201315 (2017).","journal-title":"JCO Clin. Cancer Inform."},{"key":"1886_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1638-4","volume":"18","author":"E Kim","year":"2017","unstructured":"Kim, E. & Nam, H. Prediction models for drug-induced hepatotoxicity by using weighted molecular fingerprints. BMC Bioinform. 18, 227 (2017).","journal-title":"BMC Bioinform."},{"key":"1886_CR54","doi-asserted-by":"publisher","first-page":"e201800098","DOI":"10.26508\/lsa.201800098","volume":"1","author":"A Lysenko","year":"2018","unstructured":"Lysenko, A., Sharma, A., Boroevich, K. A. & Tsunoda, T. An integrative machine learning approach for prediction of toxicity-related drug safety. Life Sci. Alliance 1, e201800098 (2018).","journal-title":"Life Sci. Alliance"},{"key":"1886_CR55","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1021\/acs.jcim.7b00641","volume":"58","author":"C Cai","year":"2018","unstructured":"Cai, C. et al. In silico pharmacoepidemiologic evaluation of drug-induced cardiovascular complications using combined classifiers. J. Chem. Inf. Model. 58, 943\u2013956 (2018).","journal-title":"J. Chem. Inf. Model."},{"key":"1886_CR56","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1039\/C7RA12957B","volume":"8","author":"X Li","year":"2018","unstructured":"Li, X. et al. The development and application of in silico models for drug induced liver injury. RSC Adv. 8, 8101\u20138111 (2018).","journal-title":"RSC Adv."},{"key":"1886_CR57","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/acs.molpharmaceut.8b01048","volume":"16","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Three-level hepatotoxicity prediction system based on adverse hepatic effects. Mol. Pharm. 16, 393\u2013408 (2019).","journal-title":"Mol. Pharm."},{"key":"1886_CR58","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/toxsci\/kfz021","volume":"169","author":"S Ramm","year":"2019","unstructured":"Ramm, S. et al. A systems toxicology approach for the prediction of kidney toxicity and its mechanisms in vitro. Toxicol. Sci. J. Soc. Toxicol. 169, 54\u201369 (2019).","journal-title":"Toxicol. Sci. J. Soc. Toxicol."},{"key":"1886_CR59","doi-asserted-by":"crossref","unstructured":"He, S. et al. An In Silico Model for Predicting Drug-Induced Hepatotoxicity. Int. J. Mol. Sci. 20, 1897 (2019).","DOI":"10.3390\/ijms20081897"},{"key":"1886_CR60","doi-asserted-by":"crossref","unstructured":"Ben Guebila, M. & Thiele, I. Predicting gastrointestinal drug effects using contextualized metabolic models. PLoS Comput Biol. 15, e1007100 (2019).","DOI":"10.1371\/journal.pcbi.1007100"},{"key":"1886_CR61","doi-asserted-by":"publisher","first-page":"25432","DOI":"10.1021\/acsomega.0c03866","volume":"5","author":"T-H Nguyen-Vo","year":"2020","unstructured":"Nguyen-Vo, T.-H. et al. Predicting drug-induced liver injury using convolutional neural network and molecular fingerprint-embedded features. ACS Omega 5, 25432\u201325439 (2020).","journal-title":"ACS Omega"},{"key":"1886_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ymeth.2020.05.013","volume":"179","author":"Y Peng","year":"2020","unstructured":"Peng, Y., Zhang, Z., Jiang, Q., Guan, J. & Zhou, S. TOP: A deep mixture representation learning method for boosting molecular toxicity prediction. Methods 179, 55\u201364 (2020).","journal-title":"Methods"},{"key":"1886_CR63","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1021\/acs.jcim.1c00451","volume":"61","author":"M de Lomana","year":"2021","unstructured":"de Lomana, M. et al. ChemBioSim: Enhancing conformal prediction of in vivo toxicity by use of predicted bioactivities. J. Chem. Inf. Model. 61, 3255\u20133272 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"1886_CR64","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00204-021-03013-3","volume":"95","author":"A Gonzalez-Jimenez","year":"2021","unstructured":"Gonzalez-Jimenez, A. et al. Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. Arch. Toxicol. 95, 1793\u20131803 (2021).","journal-title":"Arch. Toxicol."},{"key":"1886_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-020-00286-z","volume":"16","author":"W Lesi\u0144ski","year":"2021","unstructured":"Lesi\u0144ski, W., Mnich, K., Goli\u0144ska, A. K. & Rudnicki, W. R. Integration of human cell lines gene expression and chemical properties of drugs for Drug Induced Liver Injury prediction. Biol. Direct 16, 2 (2021).","journal-title":"Biol. Direct"},{"key":"1886_CR66","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/cpt.2511","volume":"111","author":"L Bedon","year":"2022","unstructured":"Bedon, L. et al. Machine learning application in a phase i clinical trial allows for the identification of clinical-biomolecular markers significantly associated with toxicity. Clin. Pharmacol. Ther. 111, 686\u2013696 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR67","doi-asserted-by":"publisher","first-page":"661075","DOI":"10.3389\/fgene.2021.661075","volume":"12","author":"W Lesi\u0144ski","year":"2021","unstructured":"Lesi\u0144ski, W., Mnich, K. & Rudnicki, W. R. Prediction of alternative drug-induced liver injury classifications using molecular descriptors, gene expression perturbation, and toxicology reports. Front. Genet. 12, 661075 (2021).","journal-title":"Front. Genet."},{"key":"1886_CR68","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.3390\/ijms22158073","volume":"22","author":"K Jaganathan","year":"2021","unstructured":"Jaganathan, K., Tayara, H. & Chong, K. T. Prediction of drug-induced liver toxicity using SVM and optimal descriptor sets. Int. J. Mol. Sci. 22, 8073 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1886_CR69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/cpt.2240","volume":"110","author":"A Fogli Iseppe","year":"2021","unstructured":"Fogli Iseppe, A. et al. Sex-specific classification of drug-induced Torsade de Pointes susceptibility using cardiac simulations and machine learning. Clin. Pharmacol. Ther. 110, 380\u2013391 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR70","doi-asserted-by":"publisher","first-page":"104122","DOI":"10.1016\/j.jbi.2022.104122","volume":"132","author":"P Joshi","year":"2022","unstructured":"Joshi, P., V, M. & Mukherjee, A. A knowledge graph embedding based approach to predict the adverse drug reactions using a deep neural network. J. Biomed. Inform. 132, 104122 (2022).","journal-title":"J. Biomed. Inform."},{"key":"1886_CR71","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/jat.4331","volume":"42","author":"Y Gong","year":"2022","unstructured":"Gong, Y. et al. In silico prediction of potential drug-induced nephrotoxicity with machine learning methods. J. Appl. Toxicol. JAT 42, 1639\u20131650 (2022).","journal-title":"J. Appl. Toxicol. JAT"},{"key":"1886_CR72","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1039\/D1LC01140E","volume":"22","author":"LH Chong","year":"2022","unstructured":"Chong, L. H. et al. Integration of a microfluidic multicellular coculture array with machine learning analysis to predict adverse cutaneous drug reactions. Lab. Chip 22, 1890\u20131904 (2022).","journal-title":"Lab. Chip"},{"key":"1886_CR73","doi-asserted-by":"crossref","unstructured":"Lim, S. et al. Supervised chemical graph mining improves drug-induced liver injuryprediction. Iscience 26, 105677 (2023).","DOI":"10.1016\/j.isci.2022.105677"},{"key":"1886_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac337","volume":"23","author":"AGC de S\u00e1","year":"2022","unstructured":"de S\u00e1, A. G. C., Long, Y., Portelli, S., Pires, D. E. V. & Ascher, D. B. toxCSM: comprehensive prediction of small molecule toxicity profiles. Brief. Bioinform. 23, bbac337 (2022).","journal-title":"Brief. Bioinform."},{"key":"1886_CR75","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/pharmaceutics15020431","volume":"15","author":"V Morozov","year":"2023","unstructured":"Morozov, V., Rodrigues, C. H. M. & Ascher, D. B. CSM-Toxin: A web-server for predicting protein toxicity. Pharmaceutics 15, 431 (2023).","journal-title":"Pharmaceutics"},{"key":"1886_CR76","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.amjmed.2023.07.019","volume":"136","author":"Y Gue","year":"2023","unstructured":"Gue, Y. et al. Machine learning predicting atrial fibrillation as an adverse event in the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. Am. J. Med. 136, 1099\u20131108.e2 (2023).","journal-title":"Am. J. Med."},{"key":"1886_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19441","volume":"9","author":"S Krix","year":"2023","unstructured":"Krix, S. et al. MultiGML: Multimodal graph machine learning for prediction of adverse drug events. Heliyon 9, e19441 (2023).","journal-title":"Heliyon"},{"key":"1886_CR78","doi-asserted-by":"crossref","unstructured":"Bangroo, I. S., Del Cid Hern\u00e1ndez, M. F., & Kumar, R. Decoding toxicological signatures through quantum computational paradigm. Opt. Quantum Electron. 56, 545 (2024).","DOI":"10.1007\/s11082-023-06079-8"},{"key":"1886_CR79","doi-asserted-by":"publisher","unstructured":"Seal, S. et al. Improved detection of drug-induced liver injury by integrating predicted in vivo and in vitro data. Chem. Res. Toxicol. https:\/\/doi.org\/10.1021\/acs.chemrestox.4c00015 (2024).","DOI":"10.1021\/acs.chemrestox.4c00015"},{"key":"1886_CR80","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1039\/D3RA07322J","volume":"14","author":"A Setiya","year":"2024","unstructured":"Setiya, A., Jani, V., Sonavane, U. & Joshi, R. MolToxPred: small molecule toxicity prediction using machine learning approach. RSC Adv. 14, 4201\u20134220 (2024).","journal-title":"RSC Adv."},{"key":"1886_CR81","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","volume":"140","author":"JR Nebeker","year":"2004","unstructured":"Nebeker, J. R., Barach, P. & Samore, M. H. Clarifying adverse drug events: a clinician\u2019s guide to terminology, documentation, and reporting. Ann. Intern. Med. 140, 795\u2013801 (2004).","journal-title":"Ann. Intern. Med."},{"key":"1886_CR82","doi-asserted-by":"crossref","unstructured":"Yazdani, A. et al. An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results. Sci. Data 12, 424 (2025).","DOI":"10.1038\/s41597-025-04718-1"},{"key":"1886_CR83","doi-asserted-by":"crossref","unstructured":"Hwang, W., Choi, J., Kwon, M. & Lee, D. Context-specific functional module based drug efficacy prediction. BMC Bioinformatics 17, 275 (2016).","DOI":"10.1186\/s12859-016-1078-6"},{"key":"1886_CR84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.artmed.2016.09.004","volume":"73","author":"M Tan","year":"2016","unstructured":"Tan, M. Prediction of anti-cancer drug response by kernelized multi-task learning. Artif. Intell. Med. 73, 70\u201377 (2016).","journal-title":"Artif. Intell. Med."},{"key":"1886_CR85","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.clinph.2018.08.014","volume":"129","author":"S Simpraga","year":"2018","unstructured":"Simpraga, S. et al. An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. Clin. Neurophysiol. J. Int. Fed. Clin. Neurophysiol. 129, 2325\u20132332 (2018).","journal-title":"Clin. Neurophysiol. J. Int. Fed. Clin. Neurophysiol."},{"key":"1886_CR86","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"BM Kuenzi","year":"2020","unstructured":"Kuenzi, B. M. et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell 38, 672\u2013684.e6 (2020).","journal-title":"Cancer Cell"},{"key":"1886_CR87","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s42256-021-00357-4","volume":"3","author":"J Lu","year":"2021","unstructured":"Lu, J., Bender, B., Jin, J. Y. & Guan, Y. Deep learning prediction of patient response time course from early data via neural-pharmacokinetic\/pharmacodynamic modelling. Nat. Mach. Intell. 3, 696\u2013704 (2021).","journal-title":"Nat. Mach. Intell."},{"key":"1886_CR88","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41587-021-00946-z","volume":"39","author":"J Zhu","year":"2021","unstructured":"Zhu, J. et al. Prediction of drug efficacy from transcriptional profiles with deep learning. Nat. Biotechnol. 39, 1444\u20131452 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1886_CR89","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/brain\/awab108","volume":"144","author":"J de Jong","year":"2021","unstructured":"de Jong, J. et al. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain J. Neurol. 144, 1738\u20131750 (2021).","journal-title":"Brain J. Neurol."},{"key":"1886_CR90","first-page":"2891","volume":"15","author":"X Shen","year":"2023","unstructured":"Shen, X. et al. Senescence-related genes define prognosis, immune contexture, and pharmacological response in gastric cancer. Aging 15, 2891\u20132905 (2023).","journal-title":"Aging"},{"key":"1886_CR91","doi-asserted-by":"publisher","unstructured":"Selvi Rajendran, P. & Sivannarayna, M. Multi-head graph attention for drug response predicton. In 3rd International Conference on Smart Data Intelligence (ICSMDI) 407\u2013414 (IEEE, 2023). https:\/\/doi.org\/10.1109\/ICSMDI57622.2023.00078.","DOI":"10.1109\/ICSMDI57622.2023.00078"},{"key":"1886_CR92","doi-asserted-by":"crossref","unstructured":"Sov\u00e9, R. J. et al. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J. Immunother. Cancer 10, e005414 (2022).","DOI":"10.1136\/jitc-2022-005414"},{"key":"1886_CR93","doi-asserted-by":"publisher","first-page":"1164482","DOI":"10.3389\/fbinf.2023.1164482","volume":"3","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Zhou, Y., Zhang, Y., Mo, Y. K. & Wang, Y. XMR: an explainable multimodal neural network for drug response prediction. Front. Bioinform. 3, 1164482 (2023).","journal-title":"Front. Bioinform."},{"key":"1886_CR94","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamapsychiatry.2017.0025","volume":"74","author":"AM Chekroud","year":"2017","unstructured":"Chekroud, A. M. et al. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry 74, 370\u2013378 (2017).","journal-title":"JAMA Psychiatry"},{"key":"1886_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06006-6","volume":"9","author":"I Dorigatti","year":"2018","unstructured":"Dorigatti, I. et al. Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning. Nat. Commun. 9, 3644 (2018).","journal-title":"Nat. Commun."},{"key":"1886_CR96","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.psychres.2020.113664","volume":"296","author":"SV Faraone","year":"2021","unstructured":"Faraone, S. V. et al. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 296, 113664 (2021).","journal-title":"Psychiatry Res."},{"key":"1886_CR97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JAD-190822","volume":"74","author":"A Ezzati","year":"2020","unstructured":"Ezzati, A. & Lipton, R. B. Machine learning predictive models can improve efficacy of clinical trials for Alzheimer\u2019s disease. J. Alzheimers Dis. JAD 74, 55\u201363 (2020).","journal-title":"J. Alzheimers Dis. JAD"},{"key":"1886_CR98","doi-asserted-by":"crossref","unstructured":"Beacher, F. D., Mujica-Parodi, L. R., Gupta, S. & Ancora, L. A. Machine learning predicts outcomes of phase iii clinical trials for prostate cancer. Algorithms 14, 147 (2021).","DOI":"10.3390\/a14050147"},{"key":"1886_CR99","first-page":"239","volume":"27","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb, A. B. et al. Secukinumab efficacy in psoriatic arthritis: machine learning and meta-analysis of four phase 3 trials. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 27, 239\u2013247 (2021).","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"1886_CR100","doi-asserted-by":"publisher","first-page":"114922","DOI":"10.1016\/j.psychres.2022.114922","volume":"318","author":"SV Faraone","year":"2022","unstructured":"Faraone, S. V. et al. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial. Psychiatry Res. 318, 114922 (2022).","journal-title":"Psychiatry Res."},{"key":"1886_CR101","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1007\/s00125-022-05748-9","volume":"65","author":"X Zou","year":"2022","unstructured":"Zou, X. et al. The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data. Diabetologia 65, 1424\u20131435 (2022).","journal-title":"Diabetologia"},{"key":"1886_CR102","doi-asserted-by":"publisher","first-page":"109550","DOI":"10.1016\/j.radonc.2023.109550","volume":"183","author":"L Li","year":"2023","unstructured":"Li, L. et al. Accurate tumor segmentation and treatment outcome prediction with DeepTOP. Radiother. Oncol. 183, 109550 (2023).","journal-title":"Radiother. Oncol."},{"key":"1886_CR103","first-page":"1","volume":"53","author":"D Lei","year":"2022","unstructured":"Lei, D. et al. Brain morphometric features predict medication response in youth with bipolar disorder: a prospective randomized clinical trial. Psychol. Med. 53, 1\u201311 (2022).","journal-title":"Psychol. Med."},{"key":"1886_CR104","doi-asserted-by":"publisher","first-page":"100385","DOI":"10.1016\/j.xops.2023.100385","volume":"4","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi, Y. et al. Machine learning to predict Faricimab treatment outcome in neovascular age-related macular degeneration. Ophthalmol. Sci. 4, 100385 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"1886_CR105","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.adg8538","volume":"383","author":"AM Chekroud","year":"2024","unstructured":"Chekroud, A. M. et al. Illusory generalizability of clinical prediction models. Science 383, 164\u2013167 (2024).","journal-title":"Science"},{"key":"1886_CR106","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1158\/1078-0432.CCR-23-3608","volume":"30","author":"T Tang","year":"2024","unstructured":"Tang, T. et al. Plasma metabolic profiles-based prediction of induction chemotherapy efficacy in nasopharyngeal carcinoma: results of a bidirectional clinical trial. Clin. Cancer Res. 30, 2925\u20132936 (2024).","journal-title":"Clin. Cancer Res"},{"key":"1886_CR107","doi-asserted-by":"publisher","first-page":"i601","DOI":"10.1093\/bioinformatics\/btaa799","volume":"36","author":"J Ubels","year":"2020","unstructured":"Ubels, J., Schaefers, T., Punt, C., Guchelaar, H. & de Ridder, J. RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. Bioinformatics 36, i601\u2013i609 (2020).","journal-title":"Bioinformatics"},{"key":"1886_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33269-x","volume":"13","author":"J-PR Falet","year":"2022","unstructured":"Falet, J.-P. R. et al. Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. Nat. Commun. 13, 5645 (2022).","journal-title":"Nat. Commun."},{"key":"1886_CR109","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/ejhf.2528","volume":"24","author":"KS Jering","year":"2022","unstructured":"Jering, K. S. et al. Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations. Eur. J. Heart Fail. 24, 1418\u20131426 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"1886_CR110","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3174\/ajnr.A7488","volume":"43","author":"E George","year":"2022","unstructured":"George, E. et al. Radiomics-based machine learning for outcome prediction in a multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. AJNR Am. J. Neuroradiol. 43, 675\u2013681 (2022).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1886_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00275-7","volume":"6","author":"T Qaiser","year":"2022","unstructured":"Qaiser, T. et al. Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials. NPJ Precis. Oncol. 6, 37 (2022).","journal-title":"NPJ Precis. Oncol."},{"key":"1886_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40218-1","volume":"13","author":"MC Ferr\u00e1ndez","year":"2023","unstructured":"Ferr\u00e1ndez, M. C. et al. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci. Rep. 13, 13111 (2023).","journal-title":"Sci. Rep."},{"key":"1886_CR113","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jtct.2024.01.079","volume":"30","author":"N Spyrou","year":"2024","unstructured":"Spyrou, N. et al. A Day 14 Endpoint for Acute GVHD Clinical Trials. Transpl. Cell Ther. 30, 421\u2013432 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"1886_CR114","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/oncolo\/oyad293","volume":"29","author":"L Gerratana","year":"2024","unstructured":"Gerratana, L. et al. Circulating tumor cells prediction in hormone receptor positive HER2-negative advanced breast cancer: a retrospective analysis of the MONARCH 2 Trial. Oncologist 29, 123\u2013131 (2024).","journal-title":"Oncologist"},{"key":"1886_CR115","doi-asserted-by":"publisher","unstructured":"Norman, P. A., Li, W., Jiang, W. & Chen, B. E. deepAFT: A nonlinear accelerated failure time model with artificial neural network. Stat. Med. https:\/\/doi.org\/10.1002\/sim.10152 (2024).","DOI":"10.1002\/sim.10152"},{"key":"1886_CR116","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300041","volume":"3","author":"RJ Desai","year":"2024","unstructured":"Desai, R. J. et al. Individualized treatment effect prediction with machine learning - salient considerations. NEJM Evid. 3, EVIDoa2300041 (2024).","journal-title":"NEJM Evid."},{"key":"1886_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105207","volume":"105","author":"J Lecuelle","year":"2024","unstructured":"Lecuelle, J. et al. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine 105, 105207 (2024).","journal-title":"EBioMedicine"},{"key":"1886_CR118","doi-asserted-by":"publisher","unstructured":"Morales, J. F. et al. Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool. CPT Pharmacomet. Syst Pharmacol https:\/\/doi.org\/10.1002\/psp4.13193 (2024).","DOI":"10.1002\/psp4.13193"},{"key":"1886_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-014-0140-0","volume":"8","author":"Y Cui","year":"2014","unstructured":"Cui, Y. et al. Multilevel modeling and value of information in clinical trial decision support. BMC Syst. Biol. 8, 6 (2014).","journal-title":"BMC Syst. Biol."},{"key":"1886_CR120","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jamia\/ocz036","volume":"26","author":"G Fang","year":"2019","unstructured":"Fang, G., Annis, I., Elston-Lafata, J. & Cykert, S. Applying machine learning to predict real-world individual treatment effects: insights from a virtual patient cohort. J. Am. Med. Inform. Assoc. 26, 977\u2013988 (2019).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1886_CR121","unstructured":"Qi, Y., Tang, Q. & 2019, undefined. Predicting phase 3 clinical trial results by modeling phase 2 clinical trial subject level data using deep learning. In Proc. Mach. Learn. Res. 106 1\u201314 (2019)."},{"key":"1886_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106364","volume":"104","author":"A Sagkriotis","year":"2021","unstructured":"Sagkriotis, A. et al. Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. Contemp. Clin. Trials 104, 106364 (2021).","journal-title":"Contemp. Clin. Trials"},{"key":"1886_CR123","doi-asserted-by":"publisher","first-page":"ooab107","DOI":"10.1093\/jamiaopen\/ooab107","volume":"5","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Carter, B. Z., Li, Z. & Huang, X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open 5, ooab107 (2022).","journal-title":"JAMIA Open"},{"key":"1886_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07801-4","volume":"12","author":"P Berchialla","year":"2022","unstructured":"Berchialla, P., Lanera, C., Sciannameo, V., Gregori, D. & Baldi, I. Prediction of treatment outcome in clinical trials under a personalized medicine perspective. Sci. Rep. 12, 4115 (2022).","journal-title":"Sci. Rep."},{"key":"1886_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-023-02207-2","volume":"23","author":"A Venkatasubramaniam","year":"2023","unstructured":"Venkatasubramaniam, A. et al. Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. BMC Med. Inform. Decis. Mak. 23, 110 (2023).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"1886_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02970-4","volume":"14","author":"K Perlman","year":"2024","unstructured":"Perlman, K. et al. Development of a differential treatment selection model for depression on consolidated and transformed clinical trial datasets. Transl. Psychiatry 14, 263 (2024).","journal-title":"Transl. Psychiatry"},{"key":"1886_CR127","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.oret.2023.11.010","volume":"8","author":"RS Chandra","year":"2024","unstructured":"Chandra, R. S. & Ying, G.-S. Predicting visual acuity responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning. Ophthalmol. Retin. 8, 419\u2013430 (2024).","journal-title":"Ophthalmol. Retin."},{"key":"1886_CR128","first-page":"1","volume":"23","author":"C Fern\u00e1ndez-Lor\u00eda","year":"2022","unstructured":"Fern\u00e1ndez-Lor\u00eda, C. & Provost, F. Causal classification: treatment effect estimation vs. outcome prediction. J. Mach. Learn. Res. 23, 1\u201335 (2022).","journal-title":"J. Mach. Learn. Res."},{"key":"1886_CR129","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.drudis.2014.06.013","volume":"19","author":"V Joshi","year":"2014","unstructured":"Joshi, V. & Milletti, F. Quantifying the probability of clinical trial success from scientific articles. Drug Discov. Today 19, 1514\u20131517 (2014).","journal-title":"Drug Discov. Today"},{"key":"1886_CR130","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cpt.194","volume":"98","author":"JA DiMasi","year":"2015","unstructured":"DiMasi, J. A. et al. A tool for predicting regulatory approval after Phase II testing of new oncology compounds. Clin. Pharmacol. Ther. 98, 506\u2013513 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR131","doi-asserted-by":"crossref","unstructured":"Lo, A., Siah, K., Wong, C. & 2018, undefined. Machine learning with statistical imputation for predicting drug approvals. Harv. Data Sci. Rev. 1, (2020).","DOI":"10.1162\/99608f92.5c5f0525\/2a3160be"},{"key":"1886_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100312","volume":"2","author":"KW Siah","year":"2021","unstructured":"Siah, K. W. et al. Predicting drug approvals: The Novartis data science and artificial intelligence challenge. Patterns N. Y. N. 2, 100312 (2021).","journal-title":"Patterns N. Y. N."},{"key":"1886_CR133","doi-asserted-by":"publisher","first-page":"670670","DOI":"10.3389\/fphar.2021.670670","volume":"12","author":"S Seo","year":"2021","unstructured":"Seo, S. et al. Predicting successes and failures of clinical trials with outer product-based convolutional neural network. Front. Pharmacol. 12, 670670 (2021).","journal-title":"Front. Pharmacol."},{"key":"1886_CR134","unstructured":"Soylemez, O. Bayesian tensor factorization for predicting clinical outcomes using integrated human genetics evidence. In The 2022 ICML Workshop on Computational Biology (2022)."},{"key":"1886_CR135","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40264-022-01160-9","volume":"45","author":"Q Xu","year":"2022","unstructured":"Xu, Q., Ahmadi, E., Amini, A., Rus, D. & Lo, A. W. Identifying and mitigating potential biases in predicting drug approvals. Drug Saf. 45, 521\u2013533 (2022).","journal-title":"Drug Saf."},{"key":"1886_CR136","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/17460441.2023.2153830","volume":"17","author":"F Ciray","year":"2022","unstructured":"Ciray, F. & Do\u011fan, T. Machine learning-based prediction of drug approvals using molecular, physicochemical, clinical trial, and patent-related features. Expert Opin. Drug Discov. 17, 1425\u20131441 (2022).","journal-title":"Expert Opin. Drug Discov."},{"key":"1886_CR137","doi-asserted-by":"publisher","unstructured":"Katsimpras, G. & Paliouras, G. Predicting intervention approval in clinical trials through multi-document summarization. 1947\u20131957 https:\/\/doi.org\/10.18653\/v1\/2022.acl-long.137 (2022).","DOI":"10.18653\/v1\/2022.acl-long.137"},{"key":"1886_CR138","doi-asserted-by":"publisher","first-page":"106494","DOI":"10.1016\/j.compbiomed.2022.106494","volume":"153","author":"L John","year":"2023","unstructured":"John, L., Mahanta, H. J., Soujanya, Y. & Sastry, G. N. Assessing machine learning approaches for predicting failures of investigational drug candidates during clinical trials. Comput. Biol. Med. 153, 106494 (2023).","journal-title":"Comput. Biol. Med."},{"key":"1886_CR139","doi-asserted-by":"publisher","first-page":"104705","DOI":"10.1016\/j.ebiom.2023.104705","volume":"94","author":"M Park","year":"2023","unstructured":"Park, M., Kim, D., Kim, I., Im, S.-H. & Kim, S. Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans. EBioMedicine 94, 104705 (2023).","journal-title":"EBioMedicine"},{"key":"1886_CR140","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2023.2230138","volume":"32","author":"L Calzetta","year":"2023","unstructured":"Calzetta, L., Pistocchini, E., Chetta, A., Rogliani, P. & Cazzola, M. Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval. Expert Opin. Investig. Drugs 32, 525\u2013536 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1886_CR141","doi-asserted-by":"publisher","first-page":"0126","DOI":"10.34133\/hds.0126","volume":"4","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Uncertainty quantification and interpretability for clinical trial approval prediction. Health Data Sci. 4, 0126 (2024).","journal-title":"Health Data Sci."},{"key":"1886_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-019-0973-y","volume":"19","author":"S Geletta","year":"2019","unstructured":"Geletta, S., Follett, L. & Laugerman, M. Latent Dirichlet Allocation in predicting clinical trial terminations. BMC Med. Inform. Decis. Mak. 19, 242 (2019).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"1886_CR143","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ipm.2018.11.009","volume":"56","author":"L Follett","year":"2019","unstructured":"Follett, L., Geletta, S. & Laugerman, M. Quantifying risk associated with clinical trial termination: A text mining approach. Inf. Process. Manag. 56, 516\u2013525 (2019).","journal-title":"Inf. Process. Manag."},{"key":"1886_CR144","doi-asserted-by":"crossref","unstructured":"Ferdowsi, S., Borissov, N., Knafou, J., Amini, P. & Teodoro, D. Classification of hierarchical text using geometric deep learning: the case of clinical trials corpus. In Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing vol. Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing 608\u2013618 (Association for Computational Linguistics, Online and Punta Cana, Dominican Republic, 2021).","DOI":"10.18653\/v1\/2021.emnlp-main.48"},{"key":"1886_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82840-x","volume":"11","author":"ME Elkin","year":"2021","unstructured":"Elkin, M. E. & Zhu, X. Predictive modeling of clinical trial terminations using feature engineering and embedding learning. Sci. Rep. 11, 3446 (2021).","journal-title":"Sci. Rep."},{"key":"1886_CR146","doi-asserted-by":"publisher","first-page":"e0253789","DOI":"10.1371\/journal.pone.0253789","volume":"16","author":"ME Elkin","year":"2021","unstructured":"Elkin, M. E. & Zhu, X. Understanding and predicting COVID-19 clinical trial completion vs. cessation. PloS One 16, e0253789 (2021).","journal-title":"PloS One"},{"key":"1886_CR147","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.patter.2022.100445","volume":"3","author":"T Fu","year":"2022","unstructured":"Fu, T., Huang, K., Xiao, C., Glass, L. M. & Sun, J. HINT: Hierarchical interaction network for clinical-trial-outcome predictions. Patterns N. Y. N. 3, 100445 (2022).","journal-title":"Patterns N. Y. N."},{"key":"1886_CR148","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1208\/s12248-022-00703-3","volume":"24","author":"K Wu","year":"2022","unstructured":"Wu, K. et al. Machine learning prediction of clinical trial operational efficiency. AAPS J. 24, 57 (2022).","journal-title":"AAPS J."},{"key":"1886_CR149","doi-asserted-by":"crossref","unstructured":"Ferdowsi, S. et al. On Graph Construction for Classification of Clinical Trials Protocols Using Graph Neural Networks. In Lecture Notes in Computer Science vol. 13263 249\u2013259 (Springer, Cham, 2022).","DOI":"10.1007\/978-3-031-09342-5_24"},{"key":"1886_CR150","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/cbdd.14092","volume":"100","author":"V Murali","year":"2022","unstructured":"Murali, V. et al. Predicting clinical trial outcomes using drug bioactivities through graph database integration and machine learning. Chem. Biol. Drug Des. 100, 169\u2013184 (2022).","journal-title":"Chem. Biol. Drug Des."},{"key":"1886_CR151","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/cts.13187","volume":"15","author":"B Kim","year":"2022","unstructured":"Kim, B. et al. Predicting completion of clinical trials in pregnant women: Cox proportional hazard and neural network models. Clin. Transl. Sci. 15, 691\u2013699 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"1886_CR152","doi-asserted-by":"crossref","unstructured":"Wang, Z. & Sun, J. Trial2Vec: Zero-Shot Clinical Trial Document Similarity Search using Self-Supervision. in Findings of the Association for Computational Linguistics: EMNLP 2022 vol. Findings of the Association for Computational Linguistics: EMNLP 2022 6377\u20136390 (Association for Computational Linguistics, Abu Dhabi, United Arab Emirates, 2022).","DOI":"10.18653\/v1\/2022.findings-emnlp.476"},{"key":"1886_CR153","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.jgo.2022.11.003","volume":"14","author":"W Lee","year":"2023","unstructured":"Lee, W., Basu, A., Carlson, J. J. & Veenstra, D. Can we predict trial failure among older adult-specific clinical trials using trial-level factors?. J. Geriatr. Oncol. 14, 101404 (2023).","journal-title":"J. Geriatr. Oncol."},{"key":"1886_CR154","doi-asserted-by":"publisher","unstructured":"Luo, J., Qiao, Z., Glass, L., Xiao, C. & Ma, F. ClinicalRisk: A New Therapy-related Clinical Trial Dataset for Predicting Trial Status and Failure Reasons. In Proceedings of the 32nd ACM International Conference on Information and Knowledge Management 5356\u20135360 https:\/\/doi.org\/10.1145\/3583780.3615113 (2023).","DOI":"10.1145\/3583780.3615113"},{"key":"1886_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2023.100689","volume":"4","author":"S Ferdowsi","year":"2023","unstructured":"Ferdowsi, S. et al. Deep learning-based risk prediction for interventional clinical trials based on protocol design: A retrospective study. Patterns N. Y. N. 4, 100689 (2023).","journal-title":"Patterns N. Y. N."},{"key":"1886_CR156","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","volume":"57","author":"E Kim","year":"2023","unstructured":"Kim, E., Yang, J., Park, S. & Shin, K. Factors Affecting Success of New Drug Clinical Trials. Ther. Innov. Regul. Sci. 57, 737\u2013750 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"1886_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27416-7","volume":"13","author":"E Kavalci","year":"2023","unstructured":"Kavalci, E. & Hartshorn, A. Improving clinical trial design using interpretable machine learning based prediction of early trial termination. Sci. Rep. 13, 121 (2023).","journal-title":"Sci. Rep."},{"key":"1886_CR158","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/cpt.3008","volume":"114","author":"A Aliper","year":"2023","unstructured":"Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972\u2013980 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1886_CR159","doi-asserted-by":"publisher","unstructured":"Wang, Z., Xiao, C. & Sun, J. SPOT: sequential predictive modeling of clinical trial outcome with meta-learning. In Proceedings of the 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics 1\u201311 https:\/\/doi.org\/10.1145\/3584371.3613001 (2023).","DOI":"10.1145\/3584371.3613001"},{"key":"1886_CR160","doi-asserted-by":"publisher","first-page":"104321","DOI":"10.1016\/j.jbi.2023.104321","volume":"139","author":"S-K Chang","year":"2023","unstructured":"Chang, S.-K. et al. Understanding common key indicators of successful and unsuccessful cancer drug trials using a contrast mining framework on ClinicalTrials. gov. J. Biomed. Inform. 139, 104321 (2023).","journal-title":"gov. J. Biomed. Inform."},{"key":"1886_CR161","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/qub2.43","volume":"12","author":"H Qi","year":"2024","unstructured":"Qi, H., Yang, W., Zou, W. & Hu, Y. A clinical trial termination prediction model based on denoising autoencoder and deep survival regression. Quant. Biol. 12, 205\u2013214 (2024).","journal-title":"Quant. Biol."},{"key":"1886_CR162","unstructured":"Zheng, W. et al. LIFTED: Multimodal mixture-of-experts for clinical trial outcome prediction. In ICML 2024 Workshop on Foundation Models in the Wild."},{"key":"1886_CR163","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43441-020-00147-x","volume":"54","author":"B Koneswarakantha","year":"2020","unstructured":"Koneswarakantha, B., M\u00e9nard, T., Rolo, D., Barmaz, Y. & Bowling, R. Harnessing the power of quality assurance data: can we use statistical modeling for quality risk assessment of clinical trials?. Ther. Innov. Regul. Sci. 54, 1227\u20131235 (2020).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"1886_CR164","doi-asserted-by":"publisher","first-page":"105851","DOI":"10.1016\/j.compbiomed.2022.105851","volume":"148","author":"T Casy","year":"2022","unstructured":"Casy, T. et al. Assessing the robustness of clinical trials by estimating Jadad\u2019s score using artificial intelligence approaches. Comput. Biol. Med. 148, 105851 (2022).","journal-title":"Comput. Biol. Med."},{"key":"1886_CR165","doi-asserted-by":"crossref","unstructured":"Wood, T. A. & McNair, D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness. Gates Open Res. 7, (2023).","DOI":"10.12688\/gatesopenres.14416.1"},{"key":"1886_CR166","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/clinpract14010007","volume":"14","author":"B Long","year":"2023","unstructured":"Long, B., Lai, S.-W., Wu, J. & Bellur, S. Predicting Phase 1 Lymphoma Clinical Trial Durations Using Machine Learning: An In-Depth Analysis and Broad Application Insights. Clin. Pract. 14, 69\u201388 (2023).","journal-title":"Clin. Pract."},{"key":"1886_CR167","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.623","volume":"7","author":"B Idnay","year":"2023","unstructured":"Idnay, B. et al. Uncovering key clinical trial features influencing recruitment. J. Clin. Transl. Sci. 7, e199 (2023).","journal-title":"J. Clin. Transl. Sci."},{"key":"1886_CR168","doi-asserted-by":"crossref","unstructured":"Theodorou, B., Glass, L., Xiao, C. & Sun, J. FRAMM: Fair ranking with missing modalities for clinical trial site selection. Patterns 5, (2024).","DOI":"10.1016\/j.patter.2024.100944"},{"key":"1886_CR169","doi-asserted-by":"crossref","unstructured":"Chiu, R. et al. Reducing Sample Size While Improving Equity in Vaccine Clinical Trials: A Machine Learning-Based Recruitment Methodology with Application to Improving Trials of Hepatitis C Virus Vaccines in People Who Inject Drugs. Healthc. Basel 12, (2024).","DOI":"10.3390\/healthcare12060644"},{"key":"1886_CR170","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436\u2013444 (2015).","journal-title":"Nature"},{"key":"1886_CR171","doi-asserted-by":"publisher","first-page":"110:1","DOI":"10.1145\/3214306","volume":"51","author":"P Wang","year":"2019","unstructured":"Wang, P., Li, Y. & Reddy, C. K. Machine Learning for Survival Analysis: A Survey. ACM Comput Surv. 51, 110:1\u2013110:36 (2019).","journal-title":"ACM Comput Surv."},{"key":"1886_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0482-1","volume":"18","author":"JL Katzman","year":"2018","unstructured":"Katzman, J. L. et al. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med. Res. Methodol. 18, 24 (2018).","journal-title":"BMC Med. Res. Methodol."},{"key":"1886_CR173","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF03037089","volume":"8","author":"S Muggleton","year":"1991","unstructured":"Muggleton, S. Inductive logic programming. N. Gener. Comput. 8, 295\u2013318 (1991).","journal-title":"N. Gener. Comput."},{"key":"1886_CR174","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/bioinformatics\/btac020","volume":"38","author":"N Brandes","year":"2022","unstructured":"Brandes, N., Ofer, D., Peleg, Y., Rappoport, N. & Linial, M. ProteinBERT: a universal deep-learning model of protein sequence and function. Bioinformatics 38, 2102\u20132110 (2022).","journal-title":"Bioinformatics"},{"key":"1886_CR175","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res 44, D1075\u2013D1079 (2016).","journal-title":"Nucleic Acids Res"},{"key":"1886_CR176","doi-asserted-by":"publisher","first-page":"103605","DOI":"10.1016\/j.drudis.2023.103605","volume":"28","author":"P Moingeon","year":"2023","unstructured":"Moingeon, P., Chenel, M., Rousseau, C., Voisin, E. & Guedj, M. Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials. Drug Discov. Today 28, 103605 (2023).","journal-title":"Drug Discov. Today"},{"key":"1886_CR177","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/ar500432k","volume":"48","author":"J-L Reymond","year":"2015","unstructured":"Reymond, J.-L. The Chemical Space Project. Acc. Chem. Res. 48, 722\u2013730 (2015).","journal-title":"Acc. Chem. Res."},{"key":"1886_CR178","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1886_CR179","unstructured":"Yazdani, A., Proios, D., Rouhizadeh, H. & Teodoro, D. Efficient Joint Learning for Clinical Named Entity Recognition and Relation Extraction Using Fourier Networks:A Use Case in Adverse Drug Events. in Proceedings of the 19th International Conference on Natural Language Processing (ICON) (eds. Akhtar, Md. S. & Chakraborty, T.) 212\u2013223 (Association for Computational Linguistics, New Delhi, India, 2022)."},{"key":"1886_CR180","doi-asserted-by":"publisher","unstructured":"Crawshaw, M. Multi-Task Learning with Deep Neural Networks: A Survey. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2009.09796 (2020).","DOI":"10.48550\/arXiv.2009.09796"},{"key":"1886_CR181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-023-00927-3","volume":"6","author":"M Giuffr\u00e8","year":"2023","unstructured":"Giuffr\u00e8, M. & Shung, D. L. Harnessing the power of synthetic data in healthcare: innovation, application, and privacy. Npj Digit. Med. 6, 1\u20138 (2023).","journal-title":"Npj Digit. Med."},{"key":"1886_CR182","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco, A. C. et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 169, 467\u2013473 (2018).","journal-title":"Ann. Intern. Med."},{"key":"1886_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001744","volume":"11","author":"KGM Moons","year":"2014","unstructured":"Moons, K. G. M. et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 11, e1001744 (2014).","journal-title":"PLoS Med"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01886-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:06:10Z","timestamp":1757322370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01886-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":183,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01886-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.21.25320310","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"486"}}